Debiopharm Underlines Commitment to Eradicating Antimicrobial Resistance by Sponsoring the 8th Annual World AMR Conference

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Infectious Diseases

General Health

Pharmaceutical

Biotechnology

2024 World AMR conference

More Like This

New report from Access to Medicine Foundation shows what pharma companies can do to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance

Debiopharm to Showcase Research Results of Their First-in-class Anti-staphylococcal Program at IDWeek 2024 in Los Angeles

CARB-X Awards Additional Funding to Debiopharm for Continued Development of Early-Stage Antibiotic Targeting Drug-Resistant N. Gonorrhoeae Infections

Over 3 million children died from AMR-related infections in 2022, major study shows

Swiss-based Non-profit GARDP Supports the Development of Debiopharm’s New Potential Treatment for Gonorrhoea

CARB-X Grants Debiopharm an Additional $12.3 Million to Advance Development of Novel Antibiotic Against Gonorrhea

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance (AMR)

Human Biome Announces Prediction of first-in class, Biosynthetic Microbiome Against Silent Pandemic of Antibiotic-Resistant Bacteria and Doses First Patients in Contextual FMT Study to validate it